Skip to content
10-K

Annual Report

PRELUDE THERAPEUTICS INC PRLD

0001193125-26-099428

← back to feed
Filed
Mar 10, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 6, 2026 63M sh
Shares Diluted FY 2025 · Dec 31, 2025 76.96M sh
Shares Diluted FY 2025 · Dec 31, 2024 75.81M sh
Capex FY 2025 · Dec 31, 2025 $67K
Capex FY 2025 · Dec 31, 2024 $764K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$56.3M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$102.89M
Cash And Equivalents FY 2025 · Dec 31, 2025 $35.26M
Cash And Equivalents FY 2025 · Dec 31, 2024 $12.47M
Stockholders Equity FY 2025 · Dec 31, 2025 $68.64M
Stockholders Equity FY 2025 · Dec 31, 2024 $131.46M
Stockholders Equity FY 2025 · Dec 31, 2023 $237.09M
Current Liabilities FY 2025 · Dec 31, 2025 $52.99M
Current Liabilities FY 2025 · Dec 31, 2024 $25.64M
Total Liabilities FY 2025 · Dec 31, 2025 $72.68M
Total Liabilities FY 2025 · Dec 31, 2024 $44.06M
Current Assets FY 2025 · Dec 31, 2025 $105.69M
Current Assets FY 2025 · Dec 31, 2024 $135.9M
Total Assets FY 2025 · Dec 31, 2025 $141.32M
Total Assets FY 2025 · Dec 31, 2024 $175.52M
Eps Diluted FY 2025 · Dec 31, 2025 −$1.29
Eps Diluted FY 2025 · Dec 31, 2024 −$1.68
Eps Basic FY 2025 · Dec 31, 2025 −$1.29
Eps Basic FY 2025 · Dec 31, 2024 −$1.68
Sga Expense FY 2025 · Dec 31, 2025 $22.41M
Sga Expense FY 2025 · Dec 31, 2024 $28.72M
Rd Expense FY 2025 · Dec 31, 2025 $94.3M
Rd Expense FY 2025 · Dec 31, 2024 $118M
Net Income FY 2025 · Dec 31, 2025 −$99.5M
Net Income FY 2025 · Dec 31, 2024 −$127.17M
Operating Income FY 2025 · Dec 31, 2025 −$104.57M
Operating Income FY 2025 · Dec 31, 2024 −$139.71M
Revenue FY 2025 · Dec 31, 2025 $12.14M
Revenue FY 2025 · Dec 31, 2024 $7M